| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/27/2007 | WO2007109172A2 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 09/27/2007 | WO2007109160A2 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 09/27/2007 | WO2007109154A2 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 09/27/2007 | WO2007109142A2 M3 muscarinic receptor antagonists for treating tumors |
| 09/27/2007 | WO2007109119A2 Neobritannilactone b and acetyl neobritannilactone b |
| 09/27/2007 | WO2007109102A2 Methods for interventions and testing for caloric restriction (cr) mimetics |
| 09/27/2007 | WO2007109098A2 HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| 09/27/2007 | WO2007109088A2 Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists |
| 09/27/2007 | WO2007109080A2 Deuterated hepatitis c protease inhibitors |
| 09/27/2007 | WO2007109071A2 Hydroxylated polymethoxyflavone compositions |
| 09/27/2007 | WO2007109057A2 Solid dosage form containing a taste masked active agent |
| 09/27/2007 | WO2007109052A2 Methods of treating lupus using cd4 antibodies |
| 09/27/2007 | WO2007109045A1 Heterocyclic organic compounds for the treatment of in particular melanoma |
| 09/27/2007 | WO2007109037A2 Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids |
| 09/27/2007 | WO2007109024A2 Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
| 09/27/2007 | WO2007108958A2 Methods of treating cancer using hypofractionated radiation and texaphyrins |
| 09/27/2007 | WO2007108947A2 Nitrofuran compounds for the treatment of cancer and angiogenesis |
| 09/27/2007 | WO2007108936A2 N-substituted-azacyclylamines as histamine-3 antagonists |
| 09/27/2007 | WO2007108883A2 High-deposition compositions and uses thereof |
| 09/27/2007 | WO2007108754A1 Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl] -lh-benzimidazol-5- yl}ethanesulfonamide salts |
| 09/27/2007 | WO2007108750A1 Pyridopyrimidine derivatives and their use as pde4 inhibitors |
| 09/27/2007 | WO2007108744A2 Novel quinazolines as 5-ht6 modulators |
| 09/27/2007 | WO2007108743A2 Novel quinazolines as 5-ht6 modulators ii |
| 09/27/2007 | WO2007108742A1 Novel tetralins as 5-ht6 modulators |
| 09/27/2007 | WO2007108727A1 Method for monitoring the effect of compounds on foxc2 expression |
| 09/27/2007 | WO2007108689A2 Method for induction of differentiation of stem and progenitor cells |
| 09/27/2007 | WO2007108633A1 A pharmaceutical composition for the treatment or prevention of allergic diseases, use thereof, and a method for treatment or prevention of allergic diseases |
| 09/27/2007 | WO2007108604A1 Pharmaceutical composition containing clopidogrel camphorsulfonate or polymorphic forms thereof |
| 09/27/2007 | WO2007108566A1 Pain-relieving composition |
| 09/27/2007 | WO2007108557A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 09/27/2007 | WO2007108541A1 Ophthalmic composition comprising xanthan gum and glucose |
| 09/27/2007 | WO2007108463A1 Solid preparation having improved solubility |
| 09/27/2007 | WO2007108442A1 Agent for prevention/treatment of irritable bowel syndrome |
| 09/27/2007 | WO2007108438A1 External composition for promoting of glutathione production and relevant method |
| 09/27/2007 | WO2007108434A1 Expression construct for digesting aggregating protein and method of inhibiting the aggregation of aggregating protein |
| 09/27/2007 | WO2007108292A1 Neurite elongation inducer |
| 09/27/2007 | WO2007108272A1 Kit for cancer therapy and pharmaceutical composition for cancer therapy |
| 09/27/2007 | WO2007108071A1 Antistress composition and food and drink containing the same |
| 09/27/2007 | WO2007108009A1 A process for purification of topiramate |
| 09/27/2007 | WO2007108004A2 S-alkylisothiouronium derivatives for the treatment of inflammatory diseases |
| 09/27/2007 | WO2007108002A2 Use of digitalis-like compounds in the treatment of affective disorders |
| 09/27/2007 | WO2007107998A1 5-aminolevulinic acid salts and their use |
| 09/27/2007 | WO2007107965A1 Cyclohexyl or piperidinyl carboxamide antibiotic derivatives |
| 09/27/2007 | WO2007107846A1 A pharmaceutical composition useful as acetyl cholinesterase inhibitors |
| 09/27/2007 | WO2007107843A1 Methods of treatment with cetp inhibitors |
| 09/27/2007 | WO2007107828A2 Amine derivatives |
| 09/27/2007 | WO2007107772A1 Salts with crth2 antagonist activity |
| 09/27/2007 | WO2007107758A1 Antibacterial agents |
| 09/27/2007 | WO2007107663A2 Use of (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide for treating inflammatory skin pathologies |
| 09/27/2007 | WO2007107598A1 Phosphorylated a2a receptor agonists |
| 09/27/2007 | WO2007107594A2 Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors |
| 09/27/2007 | WO2007107567A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine |
| 09/27/2007 | WO2007107566A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine |
| 09/27/2007 | WO2007107565A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine |
| 09/27/2007 | WO2007107550A1 Adamantane derivatives for the treatment of the metabolic syndrome |
| 09/27/2007 | WO2007107545A1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
| 09/27/2007 | WO2007107543A1 Inhibitors of the interaction between mdm2 and p53 |
| 09/27/2007 | WO2007107539A1 Compounds which potentiate ampa receptor and uses thereof in medicine |
| 09/27/2007 | WO2007107499A1 Quinoline derivatives useful as pde4 inhibitors |
| 09/27/2007 | WO2007107469A1 Methods of inhibiting btk and syk protein kinases |
| 09/27/2007 | WO2007107384A2 Soluble adenylate cyclase inhibitors |
| 09/27/2007 | WO2007107383A1 Indole derivatives as inhibitors of the soluble adenylate cyclase |
| 09/27/2007 | WO2007107373A1 Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
| 09/27/2007 | WO2007107354A1 Rosiglitazone hydrochloride hemihydrate |
| 09/27/2007 | WO2007107346A1 Substituted indazole derivatives, their manufacture and use as pharmaceutical agents |
| 09/27/2007 | WO2007107319A1 Isolation, structure determination, synthesis and bioactivity of damipipecolin and damituricin |
| 09/27/2007 | WO2007107318A1 Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one jak3 kinase inhibitor for treating autoimmune disorders |
| 09/27/2007 | WO2007107317A1 Salt of aliskiren with sulfuric acid |
| 09/27/2007 | WO2007107305A2 Treatment of triple receptor negative breast cancer |
| 09/27/2007 | WO2007107298A1 Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents |
| 09/27/2007 | WO2007107291A2 Agents for influencing receptors and consequences thereof |
| 09/27/2007 | WO2007107285A1 Lipid a antagonists with anti-septic shock, anti-inflammatory, anti-ischemia and analgesic activity |
| 09/27/2007 | WO2007107246A2 SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM |
| 09/27/2007 | WO2007107245A1 Substituted 1-amino-4-phenyl-dihydroisoquinolines, method for the production thereof, use thereof as a medicament, and medicaments containing them |
| 09/27/2007 | WO2007107243A1 Substituted chromanol derivatives and their use |
| 09/27/2007 | WO2007107221A1 4-(pyrrolopyridinyl)pyrimidinyl-2-amine derivatives |
| 09/27/2007 | WO2007107184A1 Treatment of poultry for increasing the feed conversion rate or for reducing the incidence of ascites |
| 09/27/2007 | WO2007107162A2 Small internally segmented interfering rna |
| 09/27/2007 | WO2007107040A1 THE USE OF GINSENOSIDE Rb2 MONOMER IN THE MANUFACTURE OF MEDICAMENTS FOR THROMBOLYSIS |
| 09/27/2007 | WO2007107008A1 Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity |
| 09/27/2007 | WO2007107005A1 Inhibitors of protein tyrosine kinase activity |
| 09/27/2007 | WO2007106997A1 Novel poly(ethylene oxide)-block-poly(ester) block copolymers |
| 09/27/2007 | WO2007106944A1 Contraceptive composition |
| 09/27/2007 | WO2007106938A1 Method of treatment or prophylaxis inflammatory pain |
| 09/27/2007 | WO2007092755A3 Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| 09/27/2007 | WO2007092458A8 Antidotes to exogenous neurotoxic agents |
| 09/27/2007 | WO2007092086A3 Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| 09/27/2007 | WO2007092065A9 Compounds and compositions as lxr modulators |
| 09/27/2007 | WO2007089715A3 Method for treatment of neuropathic pain |
| 09/27/2007 | WO2007089149A3 Water-soluble cc-1065 analogs and their conjugates |
| 09/27/2007 | WO2007087548A9 Chemical compounds |
| 09/27/2007 | WO2007084557A3 Azaindoles useful as inhibitors of janus kinases |
| 09/27/2007 | WO2007080598A3 A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis. |
| 09/27/2007 | WO2007079929A3 Substituted tricyclic piperidone derivatives |
| 09/27/2007 | WO2007079164A3 Protein kinase inhibitors |
| 09/27/2007 | WO2007070589A3 Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine |
| 09/27/2007 | WO2007068728A3 N-substituted pyrrolopyridinones active as kinase inhibitors |
| 09/27/2007 | WO2007067495A3 Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| 09/27/2007 | WO2007062874B1 Sulfamoyl sulfonate prodrugs |
| 09/27/2007 | WO2007062435A3 Patch |